Cafepharma Today

June 3 2025 - Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech
Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech
Arrowhead commences dosing in Phase I/IIa obesity treatment trial
ASCO: Bristol Myers CMO brushes off LAG-3 concern in lung cancer after Opdualag's adjuvant melanoma flop
Amid staff cuts, FDA looks to AI to 'optimize' reviews
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Johnson & Johnson Must Remedy Weak Organic Growth
TheStreet.com
Monday, October 14, 2013 - 8:47am
tags:
JNJ
China Biotech In Review: Hutchison MediPharma Partners Cancer Drug With Lilly
Seeking Alpha
Sunday, October 13, 2013 - 12:53pm
tags:
Hutchison MediPharma, Chi-Med, Aslan Pharma, Eddingpharm, Shenzhen Chipscreen Biosciences, Sihuan Pharma, China National Biotech Group
3 Humongous Health-Care Stocks This Week
Motley Fool
Sunday, October 13, 2013 - 12:08pm
tags:
TherapeuticsMD, Aratana, Cell Therapeutics
3 Horrendous Health-Care Stocks This Week
Motley Fool
Sunday, October 13, 2013 - 12:06pm
tags:
Ariad, Acadia, Idenix
Otsuka Pharmaceutical Completes Acquisition of Astex Pharmaceuticals
Pharmiweb
Saturday, October 12, 2013 - 12:02pm
tags:
Otsuka, Astex, M&A
Celtaxsys begins first clinical trial of CTX-4430 in cystic fibrosis patients
Pharmaceutical Business Review
Saturday, October 12, 2013 - 12:00pm
tags:
Celtaxsys, CTX-4430, cystic fibrosis
Will Johnson & Johnson Earnings Top Pfizer and Merck?
Motley Fool
Saturday, October 12, 2013 - 11:58am
tags:
JNJ
How the FDA Ruined Amarin's Day
Motley Fool
Saturday, October 12, 2013 - 11:56am
tags:
Amarin, FDA, Vascepa
Biogen Idec Dominant Player In Multiple Sclerosis Market
investors.com
Saturday, October 12, 2013 - 11:55am
tags:
Biogen Idec, MS, multiple sclerosis
Cramer: Bet on Johnson & Johnson (video)
The Street
Saturday, October 12, 2013 - 11:54am
tags:
JNJ
Why J&J Is Poised to Outperform
Motley Fool
Saturday, October 12, 2013 - 11:53am
tags:
JNJ
Amarin Will Receive A Positive Vote By The Advisory Committee
Seeking Alpha
Saturday, October 12, 2013 - 11:52am
tags:
Amarin
Is This Single-Drug Company Still a Good Investment?
Motley Fool
Saturday, October 12, 2013 - 10:36am
tags:
Questcor Pharmaceuticals
CytRx Announces Exercise of Underwriters’ Over-Allotment Option
Yahoo/BusinessWire
Saturday, October 12, 2013 - 10:35am
tags:
CytRx
Down 20%: Ariad Pharmaceuticals' Second Dose of Bad News
Motley Fool
Saturday, October 12, 2013 - 10:34am
tags:
Ariad Pharma
Data on Auxilium Pharma's Xiaflex
Yahoo/Zacks
Saturday, October 12, 2013 - 10:27am
tags:
Auxilium, Xiaflex, Dupuytren's Contracture
Is Questcor a Good Investment?
Motley Fool
Saturday, October 12, 2013 - 10:25am
tags:
Questcor Pharmaceuticals
KV's first steps after emerging from bankruptcy
Bizjournals.com
Friday, October 11, 2013 - 12:16pm
tags:
KV Pharmaceutical, bankruptcy
Med tech's hottest takeover targets for the rest of 2013
Fierce Medical Devices
Friday, October 11, 2013 - 12:14pm
tags:
devices, Baxter International, Mako Surgical, KKR, M&A
FDA's Woodcock: I'm not going anywhere
Fierce Biotech
Friday, October 11, 2013 - 12:08pm
tags:
FDA, Janet Woodcock

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.